Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

New Taipei City, Taiwan, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that its subsidiary, Health Ever Bio-Tech Co., Ltd., has been honored with the Innovation Gold Award for the development of its oral plant-derived investigational new drug BOTRESO^® for the treatment of benign prostatic hyperplasia (BPH) / lower urinary tract syndrome (LUTS), in the Pharmaceutical Category at the 2025 Taipei Biotech Awards, an event widely recognized as the “Oscars of Taiwan’s biotech industry.” The Gold Award, carrying a cash prize of more than US$26,000, was presented by Taipei City Mayor Wayne Chiang during the awards ceremony to recognize outstanding achievements in innovation and cross-disciplinary excellence in the biotech field.

Read more at globenewswire.com